Loading
A phase 2 trial of camrelizumab, everolimus, TQB2102 and TQB2868 in triple-negative breast cancer, run by Fudan University, now recruiting.
FUSCC Refractory TNBC Platform Study (FUTURE2.0) is a phase 2, interventional study registered as NCT05749588 by Fudan University, with a registry enrolment figure of 120 participants, started 2023-03-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: A1: SHR-A1811; A2: SHR-A1811 with Camrelizumab with famitinib; B1: TROP2 ADC; B2: TROP2 ADC with Camrelizumab; C1: SHR-A1811; C2: SHR-A1811 with BP102; D1: TROP2 ADC; D2: TROP2 ADC with BP102; E1: SHR-A1811; F1: TROP2 ADC; G1: SHR-A1811; H1: TROP2 ADC; E2: SHR-A1811 with everolimus; TQB2102 with TQB2868. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "TNBC invasive breast cancer confirmed by histology (specific definition: ER \<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \<1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negat". Sites: China. No results are recorded here; the registry entry is the source.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Camrelizumab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares TQB2102, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.